Vargatef^® (nintedanib) is a triple angiokinase inhibitor which targets the three key receptors involved in angiogenesis and tumour growth. Nintedanib* in combination with docetaxel is approved in the European Union (EU) for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy

*Nintedanib is approved in the EU under the brand name Vargatef^® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy.